New Autopen 24® for use with Lantus® (insuline glargine) now available in Canada
October 31, 2006
Autopen 24®, a new pen delivery system for use with Lantus®, a once-daily basal insulin, is now available in Canada for patients with type 1 and type 2 diabetes. Lantus had previously been available in Canada in vial format for use with syringes only.
“This new device makes insulin delivery a better experience for patients,” says Carolyn Lawton, a diabetes nurse practitioner at Sunnybrook Health Sciences Centre in Toronto. “The pen is more accurate than a syringe, so patients have less worry about making injection errors. It’s easy, discrete and safe to use, and will help patients who might find daily injections challenging or difficult while on the go.”
The Autopen 24, manufactured by Owen Mumford and distributed by sanofi-aventis Canada Inc., is reusable, lightweight and easy-to-use. It provides a low-force, automatic injection designed for use with a 3 mL Lantus disposable insulin cartridge. This pen delivery device is available in two dosing options and provides up to 21 U per injection in 1-unit increments or up to 42 U per injection in 2-unit increments. The Autopen 24 offers effortless insulin delivery for patients who suffer from the debilitating effects of diabetes.
“Using the pen makes my life less complicated,” says Coleman Romalis, a person living with type 1 diabetes. “Lantus has been very effective in helping me manage my diabetes, but until now I've had to make do with a syringe and needles. I've been waiting for the arrival of a pen device, and I’m glad that it's here.”
The Canadian Diabetes Association estimates that over two million Canadians have type 1 or type 2 diabetes, a number expected to rise to three million by 2010 . Diabetes is the seventh leading cause of death in Canada ; Canadian adults with diabetes are twice as likely to die prematurely, compared to persons without diabetes . Health Canada recognizes that the growth of diabetes is at epidemic levels with 60,000 new cases of type 2 diabetes yearly . Health Canada also states that Canadian healthcare costs for managing diabetes and its complications amount to more than $9 billion annually .
Sanofi-aventis is the world’s third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, internal medicine, and vaccines. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).
In Canada, sanofi-aventis Canada Inc. employs over 1,140 people and has its headquarters in Laval, Quebec.
 Canadian Diabetes Association website
 Health Canada website